Novartis expanded its collaboration with Monte Rosa Therapeutics through a second deal worth $120 million upfront and potential total payments exceeding $5.7 billion. The agreement grants Novartis exclusive licensing rights to an undisclosed target and options to license additional preclinical immunology programs. Monte Rosa will handle discovery and early testing, with Novartis advancing programs it licenses. This follows positive phase 1 data for Monte Rosa’s VAV1-targeted therapies and underscores Novartis’s commitment to targeted protein degradation as a promising approach for immune diseases. The financial infusion provides Monte Rosa runway into phase 2 trials for multiple candidates, signaling continued momentum in molecular glue drug development.